156 related articles for article (PubMed ID: 30319400)
1. Metronomic Four-Drug Regimen Has Anti-tumor Activity in Pediatric Low-Grade Glioma; The Results of a Phase II Clinical Trial.
Verschuur A; Heng-Maillard MA; Dory-Lautrec P; Truillet R; Jouve E; Chastagner P; Leblond P; Aerts I; Honoré S; Entz-Werle N; Sirvent N; Gentet JC; Corradini N; André N
Front Pharmacol; 2018; 9():00950. PubMed ID: 30319400
[No Abstract] [Full Text] [Related]
2. SFCE METRO-01 four-drug metronomic regimen phase II trial for pediatric extracranial tumor.
Heng-Maillard MA; Verschuur A; Aschero A; Dabadie A; Jouve E; Chastagner P; Leblond P; Aerts I; De Luca B; André N
Pediatr Blood Cancer; 2019 Jul; 66(7):e27693. PubMed ID: 30920117
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.
Robison NJ; Campigotto F; Chi SN; Manley PE; Turner CD; Zimmerman MA; Chordas CA; Werger AM; Allen JC; Goldman S; Rubin JB; Isakoff MS; Pan WJ; Khatib ZA; Comito MA; Bendel AE; Pietrantonio JB; Kondrat L; Hubbs SM; Neuberg DS; Kieran MW
Pediatr Blood Cancer; 2014 Apr; 61(4):636-42. PubMed ID: 24123865
[TBL] [Abstract][Full Text] [Related]
4. Pilot study of a pediatric metronomic 4-drug regimen.
André N; Abed S; Orbach D; Alla CA; Padovani L; Pasquier E; Gentet JC; Verschuur A
Oncotarget; 2011 Dec; 2(12):960-5. PubMed ID: 22156656
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors.
Qayed M; Cash T; Tighiouart M; MacDonald TJ; Goldsmith KC; Tanos R; Kean L; Watkins B; Suessmuth Y; Wetmore C; Katzenstein HM
Pediatr Blood Cancer; 2020 Apr; 67(4):e28134. PubMed ID: 31876107
[TBL] [Abstract][Full Text] [Related]
6. Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial.
Peyrl A; Chocholous M; Sabel M; Lassaletta A; Sterba J; Leblond P; Nysom K; Torsvik I; Chi SN; Perwein T; Jones N; Holm S; Nyman P; Mörse H; Öberg A; Weiler-Wichtl L; Leiss U; Haberler C; Schmook MT; Mayr L; Dieckmann K; Kool M; Gojo J; Azizi AA; André N; Kieran M; Slavc I
JAMA Oncol; 2023 Dec; 9(12):1688-1695. PubMed ID: 37883081
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma.
Bouffet E; Jakacki R; Goldman S; Hargrave D; Hawkins C; Shroff M; Hukin J; Bartels U; Foreman N; Kellie S; Hilden J; Etzl M; Wilson B; Stephens D; Tabori U; Baruchel S
J Clin Oncol; 2012 Apr; 30(12):1358-63. PubMed ID: 22393086
[TBL] [Abstract][Full Text] [Related]
8. Children treated with metronomic chemotherapy in a low-income country: METRO-MALI-01.
Fousseyni T; Diawara M; Pasquier E; André N
J Pediatr Hematol Oncol; 2011 Jan; 33(1):31-4. PubMed ID: 21164360
[TBL] [Abstract][Full Text] [Related]
9. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
10. METRO-PD1: Phase 1 study of nivolumab in combination with metronomic chemotherapy in children and adolescents with relapsing/refractory solid tumors.
André N; Deley MCL; Léguillette C; Probst A; Willems L; Travers R; Aerts I; Faure-Conter C; Revond-Riviere G; Min V; Geoerger B; Chastagner P; Entz-Werlé N; Leblond P
Eur J Cancer; 2024 Feb; 198():113525. PubMed ID: 38199147
[TBL] [Abstract][Full Text] [Related]
11. Phase I Study of a Combination of Fluvastatin and Celecoxib in Children with Relapsing/Refractory Low-Grade or High-Grade Glioma (FLUVABREX).
Leblond P; Tresch-Bruneel E; Probst A; Néant N; Solas C; Sterin A; Boulanger T; Aerts I; Faure-Conter C; Bertozzi AI; Chastagner P; Entz-Werlé N; De Carli E; Deley ML; Bouche G; André N
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046681
[TBL] [Abstract][Full Text] [Related]
12. Metronomic etoposide/cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: a preliminary monocentric study.
André N; Rome A; Coze C; Padovani L; Pasquier E; Camoin L; Gentet JC
Clin Ther; 2008 Jul; 30(7):1336-40. PubMed ID: 18691994
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study.
Hurwitz CA; Strauss LC; Kepner J; Kretschmar C; Harris MB; Friedman H; Kun L; Kadota R
J Pediatr Hematol Oncol; 2001; 23(5):277-81. PubMed ID: 11464982
[TBL] [Abstract][Full Text] [Related]
14. Low grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy -- report from the multicenter treatment study for children and adolescents with a low grade glioma -- HIT-LGG 1996 -- of the Society of Pediatric Oncology and Hematology (GPOH).
Gnekow AK; Kortmann RD; Pietsch T; Emser A
Klin Padiatr; 2004; 216(6):331-42. PubMed ID: 15565548
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.
Kesari S; Schiff D; Doherty L; Gigas DC; Batchelor TT; Muzikansky A; O'Neill A; Drappatz J; Chen-Plotkin AS; Ramakrishna N; Weiss SE; Levy B; Bradshaw J; Kracher J; Laforme A; Black PM; Folkman J; Kieran M; Wen PY
Neuro Oncol; 2007 Jul; 9(3):354-63. PubMed ID: 17452651
[TBL] [Abstract][Full Text] [Related]
16. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
Fangusaro J; Onar-Thomas A; Young Poussaint T; Wu S; Ligon AH; Lindeman N; Banerjee A; Packer RJ; Kilburn LB; Goldman S; Pollack IF; Qaddoumi I; Jakacki RI; Fisher PG; Dhall G; Baxter P; Kreissman SG; Stewart CF; Jones DTW; Pfister SM; Vezina G; Stern JS; Panigrahy A; Patay Z; Tamrazi B; Jones JY; Haque SS; Enterline DS; Cha S; Fisher MJ; Doyle LA; Smith M; Dunkel IJ; Fouladi M
Lancet Oncol; 2019 Jul; 20(7):1011-1022. PubMed ID: 31151904
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study.
Fouladi M; Nicholson HS; Zhou T; Laningham F; Helton KJ; Holmes E; Cohen K; Speights RA; Wright J; Pollack IF;
Cancer; 2007 Dec; 110(11):2535-41. PubMed ID: 17932894
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors.
Fangusaro J; Cefalo MG; Garré ML; Marshall LV; Massimino M; Benettaib B; Biserna N; Poon J; Quan J; Conlin E; Lewandowski J; Simcock M; Jeste N; Hargrave DR; Doz F; Warren KE
Front Oncol; 2021; 11():660892. PubMed ID: 34168987
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of high-dose celecoxib and metronomic 'low-dose' cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma.
El Bary NA; Hashem T; Metwally H; Ghany AA; El Mageed HA
Hematol Oncol Stem Cell Ther; 2010; 3(1):13-8. PubMed ID: 20231809
[TBL] [Abstract][Full Text] [Related]
20. Retrospective National "Real Life" Experience of the SFCE with the Metronomic MEMMAT and MEMMAT-like Protocol.
Winnicki C; Leblond P; Bourdeaut F; Pagnier A; Paluenzela G; Chastagner P; Duhil-De Benaze G; Min V; Sudour-Bonnange H; Piette C; Entz-Werle N; Chabaud S; André N
J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36835950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
